




# Case management indicator review

**Erin Eckert, MPH, PhD**

CMWG Annual Meeting  
Accra, Ghana, 22 August 2023





# OVERVIEW

- Summary of the issues
- Indicator review methods
- Finding
- Considerations for improvement



# CURRENT MEASUREMENT ISSUES

## Facility level data:

- Developed from early days when diagnostics were not readily available
- Emphasis on epidemiologic data, not performance management data;
- Suffer from perception of poor quality
- Lack of standardization, little linkage with other supporting data (LMIS, lab, etc.)

## Survey data:

- Most reliable and robust data source for some questions
- Biomarker measurement: malaria/anemia
- Self-reported data on for CM questions;
- Data only available every 3-5 years so not actionable for performance management

## Quality of Care data:

- increased data collection, used locally for program mgmt



Photo: PSI/Impact Malaria







## METHODS

- Desk reviews of existing guidance on indicators for description, definition, calculation
- Key informant interviews with NMCPs, donors, implementing partners
- Focus groups on key topics
- Field visit in Madagascar and Tanzania

*NB: Much of this information comes from a project supporting the Global Fund to review its indicators and measurement issues.*







# Proposed indicator revisions for Global Fund fall into 4 categories

CATEGORY	NUMBER OF INDICATORS	EXAMPLE
 <b>Wording Change</b>	28	<b>Malaria I-15:</b> Number of locally acquired malaria cases  Suggested change: Number of locally acquired malaria cases (pre-elimination and elimination settings)
 <b>Data Collection Improvement</b>	15	<b>Malaria O-2:</b> Proportion of the population with access to an ITN within their household  Suggested Improvement: Consider more frequent data collection through LQAS or mobile phone surveys
 <b>Remove from Framework</b>	14	<b>Malaria I-2:</b> Confirmed malaria cases (microscopy or RDT): rate per 1000 persons  Reason: Direct overlap with Malaria I-10: Annual parasite incidence confirmed malaria cases (microscopy or RDT): rate per 1000 persons/year (elimination settings)
 <b>No Change</b>	10	<b>Malaria I-4:</b> Malaria test positivity rate




# Indicators from existing sources could fill gaps in the Modular Framework



Example Gaps in Modular Framework	Examples of Potential Indicators from Existing Sources
 <p><b>Vector Control:</b> No indicators for entomological data</p>	<ul style="list-style-type: none"> <li>Resistance status* (by chemical type and subnational area) (Entomological Surveillance Planning Tool (ESPT) guide for routine entomological surveillance for decision making)</li> </ul>
 <p><b>Case Management:</b> Insufficient outcome indicators to measure quality of care; existing supervision data underutilized</p>	<ul style="list-style-type: none"> <li>Proportion of supervised health workers demonstrating competency in uncomplicated malaria case management (Supervision Data)</li> </ul>
 <p><b>Specific Prevention Interventions:</b> Indicators needed for newer interventions, including malaria vaccines and Perennial Malaria Chemoprevention</p>	<ul style="list-style-type: none"> <li>Number and % of children in the target age group who received the full number of malaria vaccine doses (Routine EPI) </li> </ul>

# MONITORING THE TREATMENT CASCADE



# CONSIDERATIONS – ROUTINE DATA

☑ Use **FEVER** instead of 'suspected case'

*Advantages:* fever is a measurable clinical sign, more objective measure

☑ Collect **AGE Group** for indicators

Either 5 year brackets, or <5, 5-10, >10

*Advantage:* allows better tracking of burden by age group

☑ Disaggregate by **GENDER/PREGNANCY STATUS**

*Advantage:* better understanding of burden and trends in subgroups,


**Caveat:** All of this requires changes to standard DHIS2 data collection, a major undertaking.



Photo: PSI/Impact Malaria



# CONSIDERATIONS – DATA SOURCES



☑ Integrate **CHW data** more completely into routine DHIS2  
*Advantage:* capturing cases treated outside a health facility

☑ Increase **PRIVATE SECTOR** reporting into routine DHIS2 reporting  
*Advantage:* capture cases treated in the private sector, more visibility into private sector practices.

☑ Encourage linkages between **LAB, PHARMACY, SUPPLY CHAIN** data systems to better understand outcomes  
*Advantage:* 360° view of strengths and weaknesses of service delivery





Photo: PSI/Impact Malaria




# CONSIDERATIONS – QUALITY OF CARE

☑ Collect and use Quality of Care data routinely.

*Advantage:* understanding the process to achieve coverage and impact

Percentage of providers competent in MIP treatment protocols from baseline to most recent supervision



Source: OTSS+/ISS data

# MONITORING VS IMPACT

## Monitoring

Purpose: performance improvement, management

Frequency: monthly, quarterly

Data Source: routine data, surveillance, supervision, campaign data

Primary Users: local health officials (district, health facility)

## Impact

Purpose: evaluation, strategy, progress towards national goals

Frequency: annually, every 3-5 years

Data Source: surveillance, surveys

Primary Users: national health authorities, donors, int'l NGOs

It is important to consider the **PURPOSE** and **USE** of the indicators that countries are asked to collect.





# FUTURE NEEDS

- Tracking subnational vaccine rollout
  - Campaigns? Health facility based?
- Monitoring multiple first line drugs
  - In elimination areas or areas where resistance has been identified
- Transition to case-based routine system for elimination




Photo: PSI/Impact Malaria





# CONNECT WITH US



**VISIT US**  
PSI.ORG




**FOLLOW US**  
@PSIIMPACT



**LIKE US**  
/PSIHEALTHYLIVES



**FOLLOW US**  
/COMPANY/POPULATION-SERVICEINTERNATIONAL



**FOLLOW US**  
@PSIIMPACT

